Subject is unable or unwilling to participate a study related procedure
Unable or unwilling to discontinue use of any drug known to be a strong or moderate inhibitor or inducer of CYP3A4 (prohibited inducers and inhibitors must be discontinued within 2 weeks prior to first dose of study drug); unable or unwilling to discontinue use of any proton pump inhibitor
Patients must not be pregnant or breast feeding, or unable or unwilling to use proper contraception during the study and up to 3 months following study completion (for treatment phase)
Patients not able or unwilling to travel for proton therapy
Unable/unwilling to undergo bone marrow sampling
Subjects must be unwilling or unable to tolerate other non-study systemic chemotherapy.
Patient is unwilling or unable to comply with study procedures, or is planning to take vacation for 7 or more consecutive days during the treatment phase of the study without prior consent from the medical monitor
For female patients of childbearing potential (defined as having had a menstrual period within the past 12 months): a positive serum pregnancy test (?-human chorionic gonadotropin [? HCG]) within 7 days prior to enrollment; or unwilling or unable to undergo hormonal suppression to avoid menstruation during treatment; or if breastfeeding, unwilling or unable to stop breastfeeding while on study treatment.
Patients unable or unwilling to adhere to the study assessment schedule.
Patients who are unwilling or unable to undergo an apheresis for production of their vaccine
Patients unable or unwilling to return to the transplant center for their assigned treatments.
Patients unable or unwilling to undergo a biopsy for research during the screening period, 2-3 weeks into the course of therapy and at the time of progression
Subjects must not be pregnant or unwilling to undergo pregnancy screening
Unable or unwilling to follow post-therapy radiation protection procedures
Unwilling or unable to discontinue disallowed disease-modifying antirheumatic drugs (DMARDs) for treatment of SSc prior to mobilization
Patient is unwilling or unable to follow the study schedule for any reason
Unable or unwilling to communicate or cooperate with the Investigator or follow the protocol for any reason
Patients who, in the investigator's judgment, are unwilling or unable to consent to and return for recommended post-treatment scans as outlined in this study
Unable or unwilling to communicate or cooperate with the Investigator or follow the protocol for any reason
Unable or unwilling to swallow the complete daily dose of ARQ 751
Patients at risk of pregnancy who are unwilling or unable to take effective contraception before rapamycin therapy, during therapy, and for 12 weeks after discontinuation of therapy
Unable or unwilling to tolerate an intracranial MRI
Subject is unable or unwilling to discontinue use of prohibited medications
Subject is unable or unwilling to participate in a study related procedure
Patient is unwilling or unable to follow the study schedule for any reason
Unwilling or unable to stop oral supplemental vitamin D
Unable to attend sessions
Unable or unwilling to swallow ARQ 092 or anastrozole or comply with chemotherapy regimen
For female patients of childbearing potential (i.e., have had a menstrual period within the past 12 months): unwilling or unable to undergo hormonal suppression to avoid menstruation during treatment.
Unable or unwilling to discontinue (and substitute if necessary) use of prohibited drugs for at least 14 days (fruits and juices for at least 7 days) prior to day 1 of FOLFIRI + bevacizumab initiation
Unwilling or unable to complete study diary
Unable or unwilling to undergo a 7 day washout period if currently being treated with deferiprone or deferoxamine or deferasirox;
Breast-feeding or pregnant women, or patients for whom there is a risk of conception and who are unable or unwilling to use appropriate contraception (for male and female patients up to 4 months after end of ibrutinib.)
Unable or unwilling to adhere to the study-specified procedures and restrictions
Patients of childbearing age who are unwilling to practice contraception or other means of avoiding pregnancy
Unable or unwilling to undergo protocol required thromboembolism prophylaxis(for Cohort C, this will be only for the subjects who have a history of VTE)
Is unable or unwilling to take folic acid or vitamin B12 supplementation.
Participants unwilling or unable to have a central venous catheter placed will not be excluded from receiving single-agent Doxil
Unwilling or unable to complete subject reported outcome assessments without assistance or with minimal assistance from trained site personnel and/or caregiver.
Is unable or unwilling to participate in a study related procedure
Patient is unwilling or unable to follow the study schedule for any reason
Male subjects unable or unwilling to use adequate contraception methods from study start to 30 days after the last dose of protocol therapy
Unable or unwilling to undergo antithrombotic prophylaxis
Unwilling to use contraceptives while on study if relevant to patient
Unable or unwilling to swallow the complete daily dose of ARQ 087
Male subjects unable or unwilling to use adequate contraception methods from study start to one year after the last dose of protocol therapy
Male subjects unable or unwilling to use adequate contraception methods from study start to one year after the last dose of protocol therapy
Male subjects unable or unwilling to use adequate contraception methods from study start to one year after the last dose of protocol therapy
Unable or unwilling to discontinue use of prohibited medications for at least 7 days prior to the first dose of study drug and for the duration of the study
Sexually active individuals capable of becoming pregnant who are unable or unwilling to use effective form(s) of contraception during time enrolled on study and for 1 year post-transplant
Patients unable or unwilling to discontinue (and substitute if necessary) use of prohibited drugs for at least 30 days prior to day 1 of FOLFIRI initiation
Patient is unable or unwilling to discontinue predefined prohibited medications listed in the protocol for 4 weeks of a drug (whichever is longer) prior to Visit 1 and for the duration of the study
EXPANSION COHORT ONLY: Patient is unable or unwilling to discontinue predefined prohibited medications listed in the protocol for 4 weeks of a drug (whichever is longer) prior to visit 1 and for the duration of the study
Unable or unwilling to adhere to the study-specified procedures and restrictions
Is unwilling or unable to abide by the requirements of the study.
Unable or unwilling to take folic acid or vitamin B12
Male subjects unable or unwilling to use adequate contraception methods from study start to one year after the last dose of protocol therapy
Subjects who are unable or unwilling to comply with all study requirements for clinical visits, examinations, tests, and procedures.
Woman of childbearing potential unwilling or unable to use adequate contraception
Unwilling or unable to take oral medication
Unable to obtain diagnostic imaging
Men unable or unwilling to employ 2 forms of highly effective contraception throughout the study and for 8 weeks after the end of study treatment
In Part 2, unable or unwilling to consent to provision of tumor tissue for GR assay
Is unwilling or unable to comply with study procedures, or is planning to take a vacation for 7 or more consecutive days during the treatment phase of the study
Patients currently taking statins who are unwilling or unable to refrain from using statins 24 hours before, the day of, and 24 hours after each MLN4924 administration
Patients who are unwilling or unable to refrain from using hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors (statins) starting 5 days before the initial study drug administration and throughout the study will not be permitted to enroll
Patients unwilling to use contraceptives while on study
Patients who are unable to take oral drugs
Unwilling or unable to have a central venous catheter
Subjects unable or unwilling to undergo antithrombotic prophylactic treatment
Patients unwilling to have a central catheter
The participant is unwilling or unable to take premedications (folic acid, vitamin B12, or corticosteroids) required by the pemetrexed label.
The subject is unable or unwilling to stop taking vitamins, herbal remedy, or nonprescription medications
Patients who are unable or unwilling to undergo antithrombotic therapy.
For female subjects of childbearing potential (i.e., have had a menstrual period within the past 12 months): a positive serum pregnancy test (?-human chorionic gonadotropin) within 7 days prior to enrollment; or unwilling or unable to undergo hormonal suppression to avoid menstruation during treatment
Unable or unwilling to discontinue use of prohibited medications for at least 28 days prior to the first dose of topotecan/pazopanib and for the duration of the study
Are unable to catheterize due to a urethral stricture disease,
Individuals that are unwilling or unable to attend study visits or are planning to move out of a study site coverage area during the subject’s anticipated participation in the study
Unwilling or unable to participate in the study
Unwilling or unable to participate in group 3RP sessions delivered via the Partners Telehealth videoconferencing software
Unwilling or unable to participate in the study
Unwilling or unable to participate in the study
Unwilling or unable to participate in the study
Unable or unwilling to discontinue consuming soy-based food or supplements while participating in this study
Unwilling to undergo phlebotomy
Unwilling or unable to stop supplemental sex hormone therapy (estrogen, progesterone, and/or testosterone preparations)
Are unable or unwilling to discontinue anxiolytics within 4 hours of education sessions
Subjects who are unable or unwilling to discontinue use of prohibited medications
Unable to cooperate with research procedures
Unwilling to receive acupuncture or unable to travel for treatments
Unwilling or unable to participate in the study
Physically unable or unwilling to participate in recommended exercise programs or travel to UCSF on a monthly basis
Patient or family is unable or unwilling to self/home administer subcutaneous experimental drug; study nurse or physician will train individuals on proper administration techniques
Be unable or unwilling to discontinue anxiolytic medication within 4 hours of intervention sessions
Is unwilling or unable to agree to swish and spit the study oral rinse three times per day during the study period
Those who are unable to understand Korean
Unable or unwilling to adhere to study-specified procedures
Unable or unwilling to adhere to a carbohydrate-restricted dietary intervention
Unable to stand without assistance
Unable to hold a breath
Patients on testosterone replacement therapy who are unwilling to discontinue
Patient under guardianship and/or unable or unwilling to cooperate with the requirements of this trial
Patients unwilling to undergo serial non-invasive imaging
Patients unwilling to undergo craniotomy
Unable to read for comprehension or completion of study documents
Are unwilling or unable to participate in, or do not have tissue adequate for participation in the biomarker analyses in the study.
Unwilling or unable to participate in the study
Unwilling or unable to receive home health care
Unable to respond to text messages and questions or unable download the study app
Fox Chase Cancer Partners sites who do not agree to chart audit procedures or providers are unable or unwilling to participate in the educational initiative
Unable to fast due to medical reason such as pregnancy
Unable to read for comprehension or completion of study documents.
Men whose partner is unwilling or unable to avoid pregnancy
Lactose-intolerance or are unwilling/unable to consume the protocol-specified standardized high-fat, high-calorie breakfast.